Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi

New Vaccines for the World's Poorest People

(2016) Peter J. Hotez et al.   Annual Review of Medicine

Chronic Chagas disease: can prophylaxis and therapeutic vaccines crack this ‘hard nut’?

(2016) Iván Bontempi et al.   Immunotherapy

Brucella abortus Omp19 recombinant protein subcutaneously co-delivered with an antigen enhances antigen-specific T helper 1 memory responses and induces protection against parasite challenge

(2016) Lorena M. Coria et al.   VACCINE

Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability

(2016) Emilia Bigaeva et al.   PLoS One

Molecular characterization and interactome analysis of Trypanosoma cruzi tryparedoxin II

(2015) Diego G. Arias et al.   Journal of Proteomics

Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy

(2015) Carlos A. Morillo et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD8+ T cells in Trypanosoma cruzi infection

(2015) Rick L. Tarleton   Seminars in Immunopathology

Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease

(2015) Iván Alejandro Bontempi et al.   VACCINE

Redox metabolism in Trypanosoma cruzi: Functional characterization of tryparedoxins revisited

(2013) Diego G. Arias et al.   FREE RADICAL BIOLOGY AND MEDICINE

Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques

(2013) Daniel DiStefano et al.   VACCINE

A brief history of the global effort to develop a preventive HIV vaccine

(2013) José Esparza   VACCINE

Mechanisms of Action of Adjuvants

(2013) Sunita Awate et al.   Frontiers in Immunology

Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects

(2012) Eric Dumonteil et al.   Expert Review of Vaccines

The recombinant gut-associated M17 leucine aminopeptidase in combination with different adjuvants confers a high level of protection against Fasciola hepatica infection in sheep

(2011) Gabriela Maggioli et al.   VACCINE

The Potential Economic Value of a Trypanosoma cruzi (Chagas Disease) Vaccine in Latin America

(2010) Bruce Y. Lee et al.   PLoS Neglected Tropical Diseases

Comparison of Recombinant Trypanosoma cruzi Peptide Mixtures versus Multiepitope Chimeric Proteins as Sensitizing Antigens for Immunodiagnosis

(2009) C. Camussone et al.   Clinical and Vaccine Immunology

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant

(2009) Eugene Maraskovsky et al.   IMMUNOLOGY AND CELL BIOLOGY

Enzymes of the antioxidant network as novel determiners of Trypanosoma cruzi virulence

(2009) L. Piacenza et al.   INTERNATIONAL JOURNAL FOR PARASITOLOGY

The development of the RTS,S malaria vaccine candidate: challenges and lessons

(2009) W. R. BALLOU   PARASITE IMMUNOLOGY

ISCOMs and ISCOMATRIX™

(2009) Hong-Xiang Sun et al.   VACCINE

Immunological Dominance of Trypanosoma cruzi Tandem Repeat Proteins

(2008) Y. Goto et al.   INFECTION AND IMMUNITY

Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: A vaccine candidate

(2008) Germán H. Fontanella et al.   VACCINE

Peroxiredoxins from Trypanosoma cruzi: Virulence factors and drug targets for treatment of Chagas disease?

(2007) María Dolores Piñeyro et al.   GENE